Evidence map›Paper›PMID 41614658›Full record

ReviewCurrent opinion in HIV and AIDS2026

Recapitulating the qualities of HIV-specific CD8 + T cells from spontaneous controllers.

Karla DeLucas, Joel N Blankson, Rachel L Rutishauser

Abstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Karla DeLucasDepartment of Medicine, University of California, San Francisco, San Francisco, California.
Joel N BlanksonDepartment of Medicine, Johns Hopkins Medicine.
Rachel L RutishauserDepartment of Medicine, University of California, San Francisco, San Francisco, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeStudies in spontaneous controllers of HIV and, more recently, post-treatment controllers have shown that effective HIV-specific CD8 + T cell responses may mediate control of the virus in the absence of antiretroviral therapy. The purpose of this review is to first discuss the unique features of HIV-specific CD8 + T cells in spontaneous controllers. We will then explore how qualities of these cells might be harnessed using T cell engineering strategies. SUMMARY OF RECENT

findingsSeveral recent studies have deepened our understanding of HIV-specific CD8 + T cell responses in spontaneous controllers. These have included studies elucidating mechanisms by which preferential antigen restriction, specificity, sensitivity, and breadth promote enhanced T cell responses in spontaneous controllers, as well as studies demonstrating that manipulating the differentiation state or localization of HIV-specific T cells might alter their ability to control the virus. In parallel, many recently-developed approaches to engineer anti-cancer T cells could be used to recapitulate key properties of HIV-specific CD8 + T cells from spontaneous controllers (e.g., sensitive antigen receptors, targeted recognition of evolutionarily conserved and/or mutationally constrained epitopes, T cell stem/memory-like functional capacity). SUMMARY: We identify several opportunities to apply novel approaches being developed in immuno-oncology to enhance the function of engineered T cells for HIV.

Indexed as

CD8-Positive T-LymphocytesElite ControllersHIV-1HIV InfectionsHumansCD8+ T cellengineered T cellspontaneous controller

Identifiers

PMID41614658
PMCPMC13048315

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.